ELISA Cohort | IHC Cohort | |||
---|---|---|---|---|
BCa (%) n = 102 | Controls (%) n = 206 | BCa (%) n = 185 | Controls (%) n = 8 | |
Median Age (range, y) | 69 (20–93) | 56 (18–89) | 73 (30–94) | 26 (21–43) |
Male: Female ratio | 84 : 18 | 152 : 54 | 143 : 42 | 4 : 4 |
Race | ||||
White | 91 (89%) | 135 (66%) | 156 (84%) | N/A |
African American | 5 (5%) | 20 (10%) | 8 (4%) | N/A |
Other | 6 (6%) | 51 (24%) | 19 (12%) | N/A |
Positive FISH | 40 / 74 (54%) | 2/22 (9%) | N/A | N/A |
Suspicious/positive cytology | 37 / 94 (39%) | 2/22 (9%) | N/A | N/A |
Median follow-up (months) | 14 | 4 | 18 | N/A |
Clinical stage | ||||
Tis | 6 (6%) | 17 (9%) | ||
Ta | 41 (40%) | 45 (24%) | ||
T1 | 14 (14%) | 63 (34%) | ||
≥T2 | 41 (40%) | 60 (33%) | ||
Tumor grade | ||||
Low | 38 (37%) | 27 (15%) | ||
High | 64 (63%) | 158 (85%) | ||
Median tumor size (cm) | 3.0 | 3.0 |